GlassScriptPhysician profile
Debra J Wallace
NPI 1033186911
$7,062.81
in general payments reported to CMS, 2019-2025
42 companies · $64.25 in 2025
The $64.25 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $1,311 · 2021: $1,508 · 2022: $903 · 2023: $858 · 2024: $1,177 · 2025: $64.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.49 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,182.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $766.00 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $634.32 | 2019-2025 | |
| Amgen INC. | $591.44 | 2019-2024 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $569.24 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.07 | 2019-2024 | Jardiance, Ofev |
| Lilly USA, LLC | $539.98 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $274.27 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $247.92 | 2019-2020 | |
| Amarin Pharma, INC. | $191.01 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $152.92 | 2021-2022 | |
| Glaxosmithkline, LLC. | $130.17 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $126.66 | 2019-2024 | Camzyos |
| Otsuka America Pharmaceutical, INC. | $120.56 | 2023-2024 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $99.19 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.